摘要
Ph样急性淋巴细胞白血病(philadelphia chromosome-like acute lym Phoblastic leukemia,Ph-like ALL)是近年来提出的一种新的急性淋巴细胞白血病亚型,其特点是Ph染色体或者BCR-ABL1融合基因阴性,但基因表达谱与Ph阳性的ALL类似,且与不良预后相关。Ph-like ALL通常可引起细胞因子受体和/或酪氨酸激酶信号的激活并级联放大,导致下游相关信号通路的活化。临床前研究显示此类白血病可能对酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)敏感。对Ph-like ALL这一高危亚型患者群体的识别,可以通过个体化的靶向治疗来改善预后,因此意义重大。本文对Ph样ALL的研究进展做一概述。
Ph- like acute lymphoblastic leukemi（ Ph- like ALL） is a recently developed new subtype of ALL,without BCR- ABL1 fusion gene. It is characterized by a gene- expression profile similar to BCR- ABL1- positive ALL,alterations of lym Phoid transcription factor genes,and a poor outcome. Ph- like ALL may lead to the persistant activation of kinase and cytokine receptor alterations as well as the activation of downstream signaling pathways. Preclinical studies have shown that Ph- like ALL can usually response to tyrosine kinase inhibitor. It is great significance to recognize this subtype of patients so that we can constitute the tailored targeted therapy to improve prognosis. In this paper,we make the research on the progress of Ph- like ALL.
出处
《现代肿瘤医学》
CAS
2017年第7期1155-1159,共5页
Journal of Modern Oncology
基金
国家自然科学基金面上项目(编号:81170519)
霍英东教育基金会高等院校青年教师基金(编号:141031)
关键词
Ph样急性淋巴细胞白血病
酪氨酸激酶抑制剂
诊断
预后
Ph-like acute lymphoblastic leukemia
tyrosine kinase inhibitors（TKIs）
diagnosis
prognosis
